​

Quest Diagnostics (DGX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

DGX Stock Forecast

Quest Diagnostics stock forecast is as follows: an average price target of $171.86 (represents a 12.25% upside from DGX’s last price of $153.10) and a rating consensus of 'Buy', based on 12 wall street analysts offering a 1-year stock forecast.

DGX Price Target

The average price target for Quest Diagnostics (DGX) is $171.86 based on 1-year price targets from 12 Wall Street analysts in the past 3 months, with a price target range of $185.00 to $160.00. This represents a potential 12.25% upside from DGX's last price of $153.10.

DGX Analyst Ratings

Buy

According to 12 Wall Street analysts, Quest Diagnostics's rating consensus is 'Buy'. The analyst rating breakdown for DGX stock is 1 'Strong Buy' (8.33%), 5 'Buy' (41.67%), 5 'Hold' (41.67%), 1 'Sell' (8.33%), and 0 'Strong Sell' (0.00%).

Quest Diagnostics Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 23, 2024Patrick DonnellyCitigroup$185.00$157.4717.48%20.84%
Oct 23, 2024Michael ChernyLeerink Partners$165.00$157.474.78%7.77%
Oct 23, 2024Stephanie DavisBarclays$168.00$157.476.69%9.73%
Oct 23, 2024Eric ColdwellRobert W. Baird$182.00$157.4715.58%18.88%
Oct 22, 2024Paige MeyerCFRA$178.00$157.4613.05%16.26%
Oct 07, 2024David MacDonaldTruist Financial$165.00$150.799.42%7.77%
Jul 29, 2024Ann HynesMizuho Securities$160.00$143.2111.72%4.51%
Jul 24, 2024Eric ColdwellRobert W. Baird$154.00$140.969.25%0.59%
Jul 15, 2024David MacDonaldTruist Financial$158.00$144.119.64%3.20%
Apr 25, 2024Stephanie DavisBarclays$144.00$137.554.69%-5.94%
Feb 07, 2024Brian TanquilutJefferies$155.00$127.4221.64%1.24%
Feb 03, 2023Wells Fargo$140.00$143.29-2.30%-8.56%
Jan 06, 2023Morgan Stanley$158.00$155.501.61%3.20%
Nov 17, 2022Citigroup$125.00$149.27-16.26%-18.35%
May 03, 2022Morgan Stanley$142.00$136.134.31%-7.25%
Apr 25, 2022Wells Fargo$150.00$133.7512.15%-2.02%
Apr 09, 2022Ralph GiacobbeCitigroup$175.00$140.0025.00%14.30%
Jan 15, 2022Pito ChickeringDeutsche Bank$190.00$142.3033.52%24.10%
Dec 13, 2021Donald HookerKeyBanc$170.00$161.755.10%11.04%
Sep 09, 2021A.J. RiceCredit Suisse$150.00$155.22-3.36%-2.02%

The latest Quest Diagnostics stock forecast, released on Oct 23, 2024 by Patrick Donnelly from Citigroup, set a price target of $185.00, which represents a 17.48% increase from the stock price at the time of the forecast ($157.47), and a 20.84% increase from DGX last price ($153.10).

Quest Diagnostics Price Target by Period

1M3M12M
# Anlaysts-611
Avg Price Target-$173.83$164.91
Last Closing Price$153.10$153.10$153.10
Upside/Downside-100.00%13.54%7.71%

In the current month, the average price target of Quest Diagnostics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Quest Diagnostics's last price of $153.10. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Oct 23, 2024CitigroupBuyBuyHold
Oct 23, 2024Leerink PartnersMarket PerformMarket PerformHold
Oct 23, 2024BarclaysEqual-WeightEqual-WeightHold
Aug 27, 2024BarclaysEqual-WeightEqual-WeightHold
Jul 29, 2024Piper SandlerNeutralNeutralHold
Jul 15, 2024Zacks Investment ResearchBuyBuyHold
Jul 10, 2024CitigroupNeutralBuyUpgrade
Jun 13, 2024CitigroupNeutralNeutralHold
May 30, 2024UBSBuyBuyHold
May 30, 2024Truist FinancialUnderperformUnderperformHold
Apr 25, 2024BarclaysEqual-WeightEqual-WeightHold
Mar 20, 2024Truist FinancialMarket PerformMarket PerformHold
Mar 20, 2024Leerink PartnersUnderperformUnderperformHold
Apr 03, 2023CitigroupUnderperformDowngrade
Apr 03, 2023Credit SuisseNeutralDowngrade
Apr 03, 2023Morgan StanleyEqual-WeightUnderweightDowngrade
Apr 03, 2023Goldman SachsBuyUpgrade
Apr 03, 2023BarclaysEqual-WeightDowngrade
Apr 03, 2023Raymond JamesStrong BuyUpgrade
Feb 03, 2023Wells FargoEqual-WeightEqual-WeightHold
Jan 06, 2023Morgan StanleyEqual-WeightEqual-WeightHold
Feb 23, 2022UBSNeutralDowngrade
Jan 15, 2022Deutsche BankBuyBuyHold

Quest Diagnostics's last stock rating was published by Citigroup on Oct 23, 2024. The company gave DGX a "Buy" rating, the same as its previous rate.

Quest Diagnostics Financial Forecast

Quest Diagnostics Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
Revenue------------$2.29B-$2.34B$2.33B$2.33B$2.49B$2.45B$2.61B$2.74B$2.77B$2.55B$2.72B$3.00B$2.79B$1.83B$1.82B$1.93B$1.96B
Avg Forecast$2.81B$2.81B$2.75B$2.71B$2.71B$2.70B$2.67B$2.62B$2.58B$2.43B$2.39B$2.29B$2.25B$2.27B$2.26B$2.20B$2.26B$2.35B$2.34B$2.64B$2.68B$2.45B$2.39B$2.64B$2.93B$2.72B$1.69B$1.75B$1.92B$1.94B
High Forecast$2.91B$2.90B$2.85B$2.80B$2.80B$2.78B$2.76B$2.72B$2.60B$2.45B$2.39B$2.29B$2.26B$2.33B$2.33B$2.27B$2.33B$2.35B$2.34B$2.64B$2.68B$2.45B$2.39B$2.64B$2.93B$2.72B$1.69B$1.75B$1.92B$1.94B
Low Forecast$2.74B$2.73B$2.68B$2.64B$2.64B$2.63B$2.60B$2.53B$2.55B$2.41B$2.39B$2.29B$2.23B$2.24B$2.20B$2.14B$2.20B$2.35B$2.34B$2.64B$2.68B$2.45B$2.39B$2.64B$2.93B$2.72B$1.69B$1.75B$1.92B$1.94B
# Analysts644643791095481366555111211109959644
Surprise %------------1.02%-1.04%1.06%1.03%1.06%1.05%0.99%1.03%1.13%1.07%1.03%1.03%1.02%1.08%1.04%1.00%1.01%

Quest Diagnostics's average Quarter revenue forecast for Mar 24 based on 4 analysts is $2.29B, with a low forecast of $2.29B, and a high forecast of $2.29B. DGX's average Quarter revenue forecast represents a -0.05% decrease compared to the company's last Quarter revenue of $2.29B (Dec 23).

Quest Diagnostics EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts644643791095481366555111211109959644
EBITDA------------$267.00M-$466.00M$419.00M$257.00M$492.00M$466.00M$595.00M$647.00M$797.00M$946.00M$761.00M$908.00M$876.00M$382.00M$251.00M$451.00M$404.00M
Avg Forecast$632.79M$631.14M$619.69M$608.76M$608.96M$606.33M$600.32M$590.34M$580.15M$547.08M$537.66M$676.43M$506.95M$510.42M$507.90M$614.94M$678.13M$530.02M$528.67M$559.03M$604.15M$553.86M$539.22M$750.74M$661.18M$614.67M$381.25M$236.90M$433.43M$438.98M
High Forecast$653.83M$652.13M$640.29M$629.00M$629.21M$626.50M$620.28M$612.95M$584.69M$551.82M$537.66M$811.72M$509.21M$523.18M$524.79M$737.92M$813.76M$530.02M$528.67M$670.84M$604.15M$553.86M$539.22M$900.89M$661.18M$614.67M$381.25M$284.28M$433.43M$438.98M
Low Forecast$616.78M$615.17M$604.01M$593.35M$593.55M$590.99M$585.13M$569.98M$573.36M$542.35M$537.66M$541.14M$502.45M$503.60M$495.05M$491.95M$542.50M$530.02M$528.67M$447.23M$604.15M$553.86M$539.22M$600.60M$661.18M$614.67M$381.25M$189.52M$433.43M$438.98M
Surprise %------------0.53%-0.92%0.68%0.38%0.93%0.88%1.06%1.07%1.44%1.75%1.01%1.37%1.43%1.00%1.06%1.04%0.92%

4 analysts predict DGX's average Quarter EBITDA for Mar 24 to be $676.43M, with a high of $811.72M and a low of $541.14M. This is 153.34% upper than Quest Diagnostics's previous annual EBITDA (Dec 23) of $267.00M.

Quest Diagnostics Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts644643791095481366555111211109959644
Net Income------------$192.00M-$235.00M$202.00M$101.00M$256.00M$234.00M$355.00M$388.00M$505.00M$631.00M$469.00M$579.00M$568.00M$185.00M$99.00M$253.00M$215.00M
Avg Forecast$295.44M$305.95M$320.83M$273.26M$278.23M$282.85M$287.70M$249.08M$246.96M$255.80M$263.83M$394.96M$238.84M$247.27M$256.15M$359.05M$408.76M$245.67M$256.63M$326.41M$360.87M$322.06M$321.54M$462.68M$467.10M$416.36M$79.76M$93.44M$179.37M$191.41M
High Forecast$308.21M$319.18M$334.69M$285.07M$290.25M$295.08M$300.14M$264.86M$248.09M$256.44M$263.84M$473.95M$243.31M$254.05M$267.22M$430.86M$490.52M$245.67M$256.63M$391.69M$360.87M$322.06M$321.54M$555.22M$467.10M$416.36M$79.76M$112.13M$179.37M$191.41M
Low Forecast$285.72M$295.89M$310.27M$264.27M$269.07M$273.55M$278.24M$243.44M$242.45M$255.16M$263.82M$315.96M$235.49M$235.98M$247.72M$287.24M$327.01M$245.67M$256.63M$261.13M$360.87M$322.06M$321.54M$370.14M$467.10M$416.36M$79.76M$74.75M$179.37M$191.41M
Surprise %------------0.80%-0.92%0.56%0.25%1.04%0.91%1.09%1.08%1.57%1.96%1.01%1.24%1.36%2.32%1.06%1.41%1.12%

Quest Diagnostics's average Quarter net income forecast for Mar 24 is $394.96M, with a range of $315.96M to $473.95M. DGX's average Quarter net income forecast represents a 105.71% increase compared to the company's last Quarter net income of $192.00M (Dec 23).

Quest Diagnostics SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts644643791095481366555111211109959644
SG&A------------$407.00M-$416.00M$439.00M$563.00M$464.00M$422.00M$425.00M$464.00M$427.00M$429.00M$407.00M$447.00M$396.00M$360.00M$377.00M$299.00M$379.00M
Avg Forecast$493.43M$492.14M$483.21M$474.69M$474.85M$472.80M$468.11M$460.32M$452.38M$426.60M$419.25M$472.83M$395.30M$398.01M$396.04M$429.85M$486.32M$411.50M$410.45M$390.77M$469.05M$430.01M$418.64M$401.51M$513.33M$477.22M$296.00M$355.82M$336.51M$340.82M
High Forecast$509.84M$508.51M$499.28M$490.47M$490.64M$488.52M$483.67M$477.96M$455.92M$430.29M$419.25M$567.40M$397.06M$407.95M$409.21M$515.82M$583.59M$411.50M$410.45M$468.93M$469.05M$430.01M$418.64M$481.82M$513.33M$477.22M$296.00M$426.98M$336.51M$340.82M
Low Forecast$480.94M$479.69M$470.98M$462.68M$462.83M$460.83M$456.26M$444.45M$447.08M$422.90M$419.25M$378.27M$391.79M$392.69M$386.02M$343.88M$389.06M$411.50M$410.45M$312.62M$469.05M$430.01M$418.64M$321.21M$513.33M$477.22M$296.00M$284.66M$336.51M$340.82M
Surprise %------------1.03%-1.05%1.02%1.16%1.13%1.03%1.09%0.99%0.99%1.02%1.01%0.87%0.83%1.22%1.06%0.89%1.11%

Quest Diagnostics's average Quarter SG&A projection for Mar 24 is $472.83M, based on 4 Wall Street analysts, with a range of $378.27M to $567.40M. The forecast indicates a 16.18% rise compared to DGX last annual SG&A of $407.00M (Dec 23).

Quest Diagnostics EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts644643791095481366555111211109959644
EPS------------$1.71-$2.08$1.80$0.89$2.20$2.00$2.97$3.18$4.11$5.05$3.52$4.28$4.20$1.38$0.74$1.88$1.59
Avg Forecast$2.61$2.71$2.84$2.42$2.46$2.50$2.55$2.20$2.19$2.26$2.33$1.86$2.11$2.19$2.27$1.97$1.91$2.19$2.29$2.99$3.22$2.88$2.87$3.71$4.17$3.72$0.71$0.88$1.60$1.71
High Forecast$2.73$2.82$2.96$2.52$2.57$2.61$2.66$2.34$2.20$2.27$2.33$1.86$2.15$2.25$2.36$2.06$1.93$2.19$2.29$2.99$3.22$2.88$2.87$3.71$4.17$3.72$0.71$0.88$1.60$1.71
Low Forecast$2.53$2.62$2.75$2.34$2.38$2.42$2.46$2.15$2.15$2.26$2.33$1.86$2.08$2.09$2.19$1.91$1.89$2.19$2.29$2.99$3.22$2.88$2.87$3.71$4.17$3.72$0.71$0.88$1.60$1.71
Surprise %------------0.81%-0.92%0.91%0.47%1.00%0.87%0.99%0.99%1.43%1.76%0.95%1.03%1.13%1.94%0.84%1.17%0.93%

According to 4 Wall Street analysts, Quest Diagnostics's projected average Quarter EPS for Mar 24 is $1.86, with a low estimate of $1.86 and a high estimate of $1.86. This represents a 8.52% increase compared to DGX previous annual EPS of $1.71 (Dec 23).

Quest Diagnostics Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
ICLRICON Public Limited Company$203.26$337.0065.80%Buy
IQVIQVIA$196.64$252.8028.56%Buy
SHCSotera Health Company$13.08$16.0022.32%Buy
IDXXIDEXX Laboratories$427.09$510.0019.41%Buy
MTDMettler-Toledo$1.25K$1.41K13.28%Hold
RVTYRevvity$114.75$127.8611.42%Buy
DGXQuest Diagnostics$155.49$171.8610.53%Buy
CRLCharles River Laboratories$189.33$209.0010.39%Buy
AAgilent$136.46$147.408.02%Buy
WATWaters$373.72$356.80-4.53%Buy
TWSTTwist Bioscience$48.40$46.00-4.96%Buy

DGX Forecast FAQ

Is Quest Diagnostics a good buy?

Yes, according to 12 Wall Street analysts, Quest Diagnostics (DGX) is considered a 'Buy'. The rating consensus is based on 1 'Strong Buy' and 5 'Buy' recommendations, accounting for 50.00% of DGX's total ratings.

What is DGX's price target?

Quest Diagnostics (DGX) average price target is $171.86 with a range of $160 to $185, implying a 12.25% from its last price of $153.1. The data is based on 12 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Quest Diagnostics stock go up soon?

According to Wall Street analysts' prediction for DGX stock, the company can go up by 12.25% (from the last price of $153.1 to the average price target of $171.86), up by 20.84% based on the highest stock price target, and up by 4.51% based on the lowest stock price target.

Can Quest Diagnostics stock reach $200?

DGX's average twelve months analyst stock price target of $171.86 does not support the claim that Quest Diagnostics can reach $200 in the near future.

What are Quest Diagnostics's analysts' financial forecasts?

Quest Diagnostics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $10.69B (high $11.06B, low $10.4B), average EBITDA is $2.41B (high $2.49B, low $2.34B), average net income is $1.1B (high $1.15B, low $1.06B), average SG&A $1.88B (high $1.94B, low $1.82B), and average EPS is $9.72 (high $10.18, low $9.42). DGX's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $11.08B (high $11.45B, low $10.8B), average EBITDA is $2.49B (high $2.58B, low $2.43B), average net income is $1.2B (high $1.25B, low $1.16B), average SG&A $1.94B (high $2.01B, low $1.89B), and average EPS is $10.58 (high $11.04, low $10.23).

Did the DGX's actual financial results beat the analysts' financial forecasts?

Based on Quest Diagnostics's last annual report (Dec 2023), the company's revenue was $9.25B, beating the average analysts forecast of $8.98B by 3.06%. Apple's EBITDA was $1.26B, missing the average prediction of $2.14B by -41.03%. The company's net income was $854M, missing the average estimation of $1.1B by -22.46%. Apple's SG&A was $1.64B, beating the average forecast of $1.62B by 1.41%. Lastly, the company's EPS was $7.63, missing the average prediction of $8.54 by -10.69%. In terms of the last quarterly report (Dec 2023), Quest Diagnostics's revenue was $2.29B, beating the average analysts' forecast of $2.25B by 1.53%. The company's EBITDA was $267M, missing the average prediction of $506.95M by -47.33%. Quest Diagnostics's net income was $192M, missing the average estimation of $238.84M by -19.61%. The company's SG&A was $407M, beating the average forecast of $395.3M by 2.96%. Lastly, the company's EPS was $1.71, missing the average prediction of $2.11 by -19.10%